Clinical trial
Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With…
NCT00138593 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00138593 |
|---|---|
| Title | Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11% |
| Official title | Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11% |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | vildagliptin |
| Enrollment | 180 |
| Start date | Jul 1, 2004 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Aug 30, 2005 |
| Last update posted | Mar 1, 2017 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: